An Innovative Plasmacytoid Dendritic Cell Line-Based Cancer Vaccine Primes and Expands Antitumor T-Cells in Melanoma Patients in a First-In-Human Trial
OncoImmunology - United States
doi 10.1080/2162402x.2020.1738812
Full Text
Open PDFAbstract
Available in full text
Date
January 1, 2020
Authors
Publisher
Informa UK Limited